gurufocus.comOct 20$ADRX

ADRX Initiates Coverage by UBS -- Price Target Set at $35.00

UBS initiated coverage on Adarx Pharmaceuticals (ADRX) with a 'Buy' rating and a $35.00 price target, citing confidence in its RNA-targeting medicines. ADRX's current price is $17.63, with a GF Score of 8/100. Insider buying totals $87.7M in the last three months. The company has a market cap of $1.95B and focuses on siRNA therapeutics for various diseases.

Original reporting

gurufocus.com

Published Oct 20, 2026, 1:00 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 20, 2026, 1:44 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefFinancial news

Primary signal

$ADRX

Bullish

high confidence

Mentioned

$ADRX

Relevance

6/10

AlphAI data visualization · based on gurufocus.com

Decision brief

The 30-second read

$ADRXBullishMed

Why it matters

UBS's new coverage could attract new capital and increase trading volume.

Market read

Analyst initiation provides a fresh catalyst for ADRX, potentially prompting price movement.

What to watch

High insider buying could be a red flag if insiders are cashing out later.

Relevance 6/10Novelty 6/10Timing: today

Background

Adarx Pharmaceuticals is a clinical‑stage biotech developing siRNA therapeutics.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ADRXBullishHigh confidence

Context

UBS initiated coverage with a Buy rating and a $35 price target, a fresh analyst upgrade for ADRX.

Expected impact

upward pressure as investors price in the new $35 target.

Evidence & confidence

Coverage initiation is a primary catalyst; the target implies ~100% upside from current price.

Market effects

Sector

May lift sentiment in the biotech/RNA therapeutics sector.

Regional

Limited to US biotech investors.

Global

Low; primarily affects ADRX and peers.

Counterpoint

What could challenge this read

The low GF Score and lack of revenue suggest caution despite the upgrade.

Key entities

company
Adarx Pharmaceuticals
Clinical‑stage biotech focused on RNA‑targeting medicines.
analyst
UBS
Investment bank that initiated coverage with a Buy rating.

Read at source ← All news

$ADRXHighAI 8/10

ADARx Advances Agazisiran, Onvuzosiran Programs; Key Clinical Readouts Set For 2027

ADARx Pharmaceuticals (ADRX) reported Q3 2026 revenue of $2.2M, up from $1.6M in 2025, with R&D and G&A expenses rising. Net loss widened to $28.1M. The company has $901M in cash and expects funds to last until 2030. ADARx advanced clinical trials for agazisiran and onvuzosiran, with key data expected in 2027. The company completed an IPO raising $513.2M and a private placement with AbbVie for $89.3M.

rttnews.comNov 13

$ADRXMed

ADARx Reports Third Quarter 2026 Financial Results and Provides Business Updates

ADARx Pharmaceuticals, Inc. (ADRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ADARx Reports Third Quarter 2026 Financial Results and Provides Business Updates – Completed initial public offering (IPO) and concurrent private placement generating aggregate gross proceeds of approximately $602.5 million; cash position expected to fund operations

SEC EDGAR 8-KNov 12

$ADRXMed

Morgan Stanley initiates ADARx stock with overweight rating

Morgan Stanley initiated coverage on ADARx Pharmaceuticals (NASDAQ:ADRX) with an overweight rating and a $32.00 price target, suggesting 81% upside. The company has a market cap of $1.98 billion and a pipeline of liver-targeted treatments. UBS and TD Cowen also initiated coverage with Buy ratings and higher price targets. ADARx recently completed an IPO, raising $446.3 million.

investing.comOct 20

$ADRXHighAI 9/10

ADARx raises $513.2M as underwriters exercise IPO option

ADARx Pharmaceuticals (NASDAQ:ADRX) raised $513.2M after underwriters exercised their option to buy 3.9M additional shares at $17.00 each in its IPO. Total shares sold reached 30.2M. AbbVie bought 5.3M shares in a private placement at the same price, adding $89.3M. Combined proceeds totaled $602.5M. J.P. Morgan, Morgan Stanley, and others managed the offering.

investing.comOct 1

$ADRXHighAI 8/10

ADARx Pharmaceuticals, Inc. (ADRX) Greenshoe Fully Exercised; IPO Gross Now ~$513.2M

ADARx Pharmaceuticals' underwriters fully exercised the greenshoe option, adding 3.94M shares to the IPO at $17 each. The total IPO size is now 30.19M shares, raising ~$513.2M. Including a concurrent private placement, total gross proceeds reached ~$602.5M, according to the company.

tradingview.comOct 1

$ADRXMedAI 9/10

ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public Offering

ADARx Pharmaceuticals (ADRX) announced the closing of an additional 3.94 million shares sold in its IPO, raising $513.2 million at $17 per share. Including a concurrent private placement, total gross proceeds reached $602.5 million. J.P. Morgan, Morgan Stanley, and others acted as underwriters.

globenewswire.comOct 1